# Phase I/II of LB-100 Plus Doxorubicin vs. Doxorubicin Alone in First Line of Advanced Soft Tissue Sarcomas

> **NCT05809830** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Grupo Espanol de Investigacion en Sarcomas** · enrollment: 152 (estimated)

## Conditions studied

- Advanced Soft-tissue Sarcoma

## Interventions

- **DRUG:** LB-100 plus Doxorrubicin
- **DRUG:** Doxorubicin

## Key facts

- **NCT ID:** NCT05809830
- **Lead sponsor:** Grupo Espanol de Investigacion en Sarcomas
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-05-29
- **Primary completion:** 2025-06-20
- **Final completion:** 2026-05-08
- **Target enrollment:** 152 (ESTIMATED)
- **Last updated:** 2025-03-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05809830

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05809830, "Phase I/II of LB-100 Plus Doxorubicin vs. Doxorubicin Alone in First Line of Advanced Soft Tissue Sarcomas". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05809830. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*